Immunotherapy

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer
Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr, Peter Duewell

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 288; DOI: 10.1186/s40425-019-0778-7
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Hamzah Abu-Sbeih, Tenglong Tang, Yang Lu, Selvi Thirumurthi, Mehmet Altan, Amir A. Jazaeri, Ramona Dadu, Emmanuel Coronel, Yinghong Wang

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 31; DOI: 10.1186/s40425-019-0502-7
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 354; DOI: 10.1186/s40425-019-0813-8
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, Raul E. Giglio, C. René Leemans, Tanguy Y. Seiwert, Denis Soulieres

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 96; DOI: 10.1186/s40425-019-0578-0
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte, L. Bonanno

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 205; DOI: 10.1186/s40425-019-0690-1
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao, Li-Wu Fu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 245; DOI: 10.1186/s40425-019-0733-7
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile, Vincenzo Esposito

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 102; DOI: 10.1186/s40425-019-0588-y
PD-L1 detection using ⁸⁹Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
Joseph Vento, Aditi Mulgaonkar, Layton Woolford, Kien Nham, Alana Christie, Aditya Bagrodia, Alberto Diaz de Leon, Raquibul Hannan, Isaac Bowman, Renee M. McKay, Payal Kapur, Guiyang Hao, Xiankai Sun, James Brugarolas

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 144; DOI: 10.1186/s40425-019-0607-z
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Gang Xiao, Li-Lian Jin, Chao-Qun Liu, Yong-Chun Wang, Ya-Ming Meng, Zhong-Guo Zhou, Jing Chen, Xing-Juan Yu, Yao-Jun Zhang, Jing Xu, Limin Zheng

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 300; DOI: 10.1186/s40425-019-0784-9
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
Michael Fehlings, Suchit Jhunjhunwala, Marcin Kowanetz, William E. O’Gorman, Priti S. Hegde, Hermi Sumatoh, Boon Heng Lee, Alessandra Nardin, Etienne Becht, Susan Flynn, Marcus Ballinger, Evan W. Newell, Mahesh Yadav

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 249; DOI: 10.1186/s40425-019-0695-9

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages